Objective: To assess the influence of craniopharyngioma or consequent surgery on melatonin secretion, and the association with fatigue, sleepiness, sleep pattern and sleep quality. Design: Cross-sectional study. Methods: A total of 15 craniopharyngioma patients were individually matched to healthy controls. In this study, 24-h salivary melatonin and cortisol were measured. Sleep-wake patterns were characterised by actigraphy and sleep diaries recorded for 2 weeks. Sleepiness, fatigue, sleep quality and general health were assessed by Multidimensional Fatigue Inventory, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and Short-Form 36. Results: Patients had increased mental fatigue, daytime dysfunction, sleep latency and lower general health (all, P%0.05), and they tended to have increased daytime sleepiness, general fatigue and impaired sleep quality compared with controls. The degree of hypothalamic injury was associated with an increased BMI and lower mental health (PZ0.01). High BMI was associated with increased daytime sleepiness, daytime dysfunction, mental fatigue and lower mental health (all, P%0.01). Low midnight melatonin was associated with reduced sleep time and efficiency (P%0.03) and a tendency for increased sleepiness, impaired sleep quality and physical health. Midnight melatonin remained independently related to sleep time after adjustment for cortisol. Three different patterns of melatonin profiles were observed; normal (nZ6), absent midnight peak (nZ6) and phase-shifted peak (nZ2). Only patients with absent midnight peak had impaired sleep quality, increased daytime sleepiness and general and mental fatigue. Conclusion: Craniopharyngioma patients present with changes in circadian pattern and daytime symptoms, which may be due to the influence of the craniopharyngioma or its treatment on the hypothalamic circadian and sleep regulatory nuclei.
be associated with a wide variety of symptoms including fatigue, disturbances in the sleep-wake regulatory system and circadian rhythms.
Craniopharyngiomas usually affect the hypothalamus indirectly, deriving from the peripituitary region from Rathke's Pouch and extending upward along the anatomical midline. In general, craniopharyngiomas are locally aggressive with finger-like attachments invading crucial structures, e.g. the hypothalamus, the pituitary, the third ventricle and the optic nerve (3) . Tumour growth or its treatment often leads to hypopituitarism, visual field defects, obesity and increased daytime sleepiness (4) . As compared with healthy controls, patients successfully treated for craniopharyngiomas had previously been reported with both normal (5) and impaired quality of life (6) , increased self-reported general and physical fatigue (7) , increased daytime sleepiness and sleep disturbances (8, 9, 10, 11, 12, 13) and increased prevalence of severe sleepiness despite normal sleep pattern (14, 15) .
Based on the present knowledge, we hypothesised that damage to the hypothalamus by local tumour compression, surgical treatment or irradiation might involve the suprachiasmatic nucleus (SCN), thereby leading to disturbed circadian function causing clinical manifestations in terms of daytime sleepiness and fatigue.
We aimed to assess the association between melatonin secretion, as a marker of the SCN function, and sleep disorders, sleep quality and daytime sleepiness in craniopharyngioma patients and healthy controls. Owing to the potential influence of cortisol on sleep (16, 17) , saliva cortisol concentrations were assessed in parallel to melatonin concentrations.
Subjects and methods
Patients treated for craniopharyngiomas were recruited from the Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Denmark. Each patient was individually matched to a healthy control by gender, race, age and BMI. Healthy controls were recruited by www.forsogsperson.dk.
The study was approved by the Local Ethical Committee (J.nr. H-3-2011-057) and the Danish Data Protection Agency (J.nr. . The study was registered at ClinicalTrials.gov (NCT01881854). All participants gave their written informed consent before enrolment after full explanation of the purpose and nature of all procedures used.
Inclusion criteria were patients treated for former craniopharyngiomas aged 18-70 years, and exclusion criteria were insufficient substitution of pituitary hormone deficiencies within 6 months before inclusion, total blindness with complete lack of perception of light and form, clinically significant liver or renal disease, use of non-steroidal anti-inflammatory drugs (NSAID) (18) , b-receptor antagonists (18) , antidepressants that affect serotonin (19) , active cancer, epileptic seizures (18) , working night shift, breast feeding, pregnancy and alcohol or drug abuse. None of the subjects reported travelling across time zones before inclusion.
A total of 55 patients were identified, of whom 31 fulfilled the inclusion criteria. Written informed consent was obtained from 16 patients. One patient died after enrolment, and the final study population thus included 15 patients and 15 matched controls. One healthy control showed severe pathological sleep characteristics. She informed that she had been diagnosed with a sleep disorder before our study; further specification unknown. As a consequence, data from this subject were omitted from further analyses.
Classification of hypothalamic injury
An assessment of the hypothalamic involvement and injury based on the preoperative findings was performed by the neurosurgeon (L Poulsgaard) and classified into three groups: i) minimal hypothalamic injury -in cases of no or very limited adhesions between the tumour and the hypothalamus; ii) moderate hypothalamic injury -in cases where the tumour adhered to the hypothalamus, but could be released with some dissections and without structural changes in the hypothalamus; and iii) severe hypothalamic injury -in cases with strong adhesions between the tumour and the hypothalamus. Dissections of the tumour caused structural changes in the hypothalamus.
Baseline assessment
Before inclusion, patients were defined with pituitary dysfunctions based on standard anterior pituitary testing. Upon inclusion, blood pressure, pulse and anthropometric profiles of weight, height and waist and hip circumferences were measured. Overnight fasting baseline pituitary hormone concentrations were measured to ensure that patients, who had insufficient pituitary hormone production, were appropriately substituted before inclusion.
in their habitual sleep environments. Fatigue, daytime sleepiness, sleep quality and general health status were evaluated by questionnaires.
Actigraphy
The sleep habits of all subjects were recorded on the non-dominant wrist using the Actiwatch (Philips Respironics, Murrysville, PA, USA) for a period of 2 weeks. Self-reported time of activities and event bottoms were used to separate sedentary activities (quiet wakefulness) from sleep (20, 21) .
Analyses were performed using the Actiware version 5.70.1, Actiwatch Communication and Sleep Analysis Software (Koninklijke Philips Electronics N.V, Amsterdam, Netherlands). The actigraphs recorded with an epoch length of 30 s. Activity count R80 of an epoch was detected as wake, and 10 min of immobility marked sleep onset and sleep end. Major rest intervals of more than three hours or minor rest intervals of less than three hours were automatically created with a minimum size of 40 min with a sensitivity setting of 'medium'. Start and end times of rest intervals were adjusted by event markers, activity counts, light and sleep diary entries.
Average activity counts per minute, total sleep time, sleep latency and sleep efficiency were calculated from the actigraphic data. Activity counts per minute were given by the sum of all valid physical activity counts for all epochs during the 2 weeks of wrist actigraphic recording divided by the total time of recording in minutes. Total sleep time was calculated by the total number of epochs scored as sleep multiplied by the epoch length of 30 s. Sleep latency was measured as the time between the start rest interval and the following sleep start. Sleep efficiency in per cent was calculated by the total sleep time divided by the time in bed times 100.
Sleep diary
In the sleep diaries, patients and healthy controls recorded the bedtime, time of sleep onset, number of awakenings during the night, wake after sleep onset, wake-up times, total time of night sleep and day naps. Sleep latency was calculated as the time interval between bedtime and sleep onset, and wake after sleep onset as the amount of time awake after first sleep entry -both rounded to the nearest minute. Total time of night sleep was the amount of actual sleep time during the night, day nap was the amount of time asleep during the day and total sleep time equalled the total amount of sleep in a 24-h period -all rounded to the nearest 0.1 h. The proportion of night sleep in the period of time spent in bed formed the sleep efficiency. Sleep efficiency was calculated as the ratio between total time of night sleep and time in bed rounded to the nearest 1.0%.
Questionnaires
The following four questionnaires were used for the assessment of fatigue, sleepiness, sleep quality and general health status: i) the 'Multidimensional Fatigue Inventory' (MFI-20) (22); ii) the 'Pittsburgh Sleep Quality Index' (PSQI) (23) , a PSQI global score O5 indicated impaired sleep quality (24, 25) ; iii) the 'Epworth Sleepiness Scale' (ESS) (26) , where cut-off scores O10 were indicative of excessive sleepiness (24, 25) ; and iv) the 'Medical Outcomes Study 36-Item Short-Form Health Survey' (SF36) (27) that used two summary component scores of overall mental and physical health derived from eight domains. Within the SF36 scores, low values indicated a lower selfrated general health. Data quality of the SF36 responses was determined using QualityMetric Health Outcomes Scoring Software 4.5 (QualityMetric, Lincoln, RI, USA).
Saliva melatonin and cortisol
During the 2 weeks of actigraphy, subjects collected eight saliva samples with a volume of 3 ml each over a 24-h period in order to measure saliva melatonin and cortisol concentrations. The samples were collected at 1200, 1600, 2000, 2200, 0000 h, 0400, 0800 and 1200 h. Saliva samples were collected at home with limited physical activity 10 min before and during saliva collection (28) . To avoid contamination of samples, the subjects were not allowed to brush teeth and consume any food products or beverages 1 h before each sample, although drinking water was permitted until 15 min before saliva collection. Subjects were told to rinse their mouth with water and avoid postural change 15 min before saliva collection. Smoking was not allowed 30 min before saliva collection. Bright light was avoided 2-3 h before bedtime. Subjects filled in the questionnaires on the first day of saliva sampling.
During the collection period, saliva samples were kept at 3-5 8C, and when all were collected, they were sent by mail to the Department of Endocrinology at Copenhagen University Hospital. Each sample was centrifuged, and the supernatant was stored at K22 8C until analysis. All samples from each subject were assayed in the same assay series within the same batch. Samples were analysed for cortisol levels at the Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet, by a competitive electrochemiluminescence immunoassay (Modular E-module; Roche Enzyme Test Cortisol, Roche Diagnostics GmbH) with coefficient of variation (CV) values of 6% (4.7 nmol/l) and 3% (11.5 nmol/l). In addition, saliva was analysed for melatonin levels at the Department of Clinical Biochemistry, Copenhagen University Hospital, Glostrup Hospital, by the Direct Saliva Melatonin RIA (Bü hlmann Laboratories AG, Schönenbuch, Switzerland) with CV values of 20.1% (0.6 pg/ml), 4.1% (3.6 pg/ml), 2.6% (7.2 pg/ml) and 4.8% (24.4 pg/ml).
Statistical analysis
With a paired design, we aimed to study the variability of within-subject differences and remove the betweensubject variability with regard to the possible influence that age, gender and BMI might have on the sleep characteristics assessed from sleep diaries, actigraphic recordings and questionnaires. Categorical data were compared by one-tailed Fisher's exact test. Between-group comparisons of normally distributed continuous data on anthropometry and biochemistry were analysed by Student's t-test or the Mann-Whitney U-test in case of the non-Gaussian distribution. Data of normally distributed sleep characteristics were analysed by the paired t-test. Intra-individual inter-daily variability of the sleep characteristics assessed from the sleep diary and actigraphy was calculated. Correlation analyses were performed to assess associations between sleep characteristics and salivary melatonin and cortisol. Data are presented as mean (S.D.) and any differences with P%0.05 were considered significant. All statistical analyses were performed using SAS version 9.1, and analyses of the actigraphy data were performed using Actiware version 5.70.1, Actiwatch Communication and Sleep Analysis Software.
Results
Patient characteristics are given in Table 1 . Seven patients were classified as with minimal hypothalamic injury, four as with moderate and three as with severe hypothalamic injury. One patient could not be classified.
Baseline assessment
Patients and healthy controls were well matched for age, BMI and waist and hip circumferences ( Table 2 ). The (Table 5) .
Saliva cortisol and melatonin
Patients had significantly higher 1200-, 2000-, 2200 hand area under the curve (AUC)-cortisol compared with controls (P%0.05; Fig. 1A ). Patients had lower AUC melatonin (PZ0.04) compared with healthy controls (Fig. 1B) .
Association of midnight cortisol and melatonin with sleep and fatigue characteristics
Correlation coefficients were calculated to measure the degree of association between midnight cortisol and melatonin concentrations and the results from sleep diaries, actigraphy and questionnaires (Table 6 ). In patients, a high midnight cortisol level was associated with an increased number of awakenings (PZ0.02) and total sleep time, although not reaching significance (PZ0.07). In healthy controls, high midnight cortisol levels were associated with lower total sleep time (PZ0.01), increased sleep latency (PZ0.03) and increased general fatigue (PZ0.03). In patients, low midnight melatonin was associated with decreased total sleep time (PZ0.03), decreased time Table 3 Hormone concentrations and hormone replacement therapy. Testing of the hypothalamic-pituitary-adrenal axis was not accessible in one patient with panhypopituitarism. It was found that 14 patients had insufficient growth hormone (GH) secretion; two patients were not substituted with GH, one due to high normal IGF1 (R1.5 S.D.) and the other did not present with symptoms of GH deficiency. All patients with insufficient secretions of antidiuretic hormone and sex hormones were appropriately substituted.
Patients
Healthy controls 
Differentials within patients
The individual day curves of melatonin were divided into three subgroups. Out of 14 patients, six had melatonin profiles similar to the healthy controls ( Fig. 2A) , six had overall low melatonin concentrations with melatonin peak values below 10 pg/ml (Fig. 2B ) and two had phase-shifted melatonin profiles (Fig. 2C) . The subgroups did not differ with regard to the severity of hypothalamic injury, number of affected pituitary axes, age and BMI. Patients with melatonin profiles similar to healthy controls showed no differences in sleep characteristics assessed from the sleep diaries, actigraphic recordings or questionnaires compared with healthy controls. However, patients with low melatonin concentrations had increased daytime sleepiness (ESS) (PZ0.03), impaired sleep quality (PSQI) (PZ0.05) and increased general fatigue and mental fatigue (MFI-20) (PZ0.08). The two patients with phase-shifted melatonin concentrations did not appear to differ from healthy controls with regard to sleep pattern and quality, fatigue and sleepiness as assessed by the applied methods.
Associations of hypothalamic injury with hormone concentrations, BMI and sleep and fatigue characteristics
The degree of hypothalamic injury was associated with an increased BMI (rZ0.69; PZ0.01), lower activity counts reflecting reduced physical activity (rZK0.47; PZ0.09) and a low mental component score indicating a lower self-rated mental health (SF36) (rZK0.84; P!0.001).
The degree of hypothalamic injury was associated with neither melatonin concentrations nor sleep characteristics assessed from the sleep diaries.
Associations of BMI with hormone concentrations and sleep and fatigue characteristics
Only in patients, a high BMI was significantly associated with increased daytime sleepiness (ESS) (rZ0.63; PZ0.01), 
Discussion
The SCN is central in sleep regulation. Blue light, acting via the retina and the retinohypothalamic projection to the SCN, is the primary synchroniser of the endogenous circadian pacemaker of the SCN. The SCN, in turn, generates the rhythm of diurnal secretion of cortisol and melatonin from the pineal gland. Rhythm generation in the SCN can be modulated in phase and amplitude by melatonin, which inhibits firing from the SCN neurons. Melatonin is thus centrally involved in sleep promotion and the regulation of the circadian rhythms (29, 30) and can be used as a marker of SCN function. Alterations in the circadian melatonin secretion rhythm have been reported in craniopharyngioma patients (14) and related to increased daytime sleepiness and BMI (4), and an improvement of the self-reported daytime hypersomnolence has been observed on melatonin substitution (9) . These data suggested that the circadian system might be involved in patients with craniopharyngiomas. However, none of the studies evaluated the cortisol or temperature rhythm expressing lesions to the SCN or its projections.
In this study, the influence of craniopharyngiomas or their treatment on melatonin secretion, as a marker of SCN function, and the association with sleep pattern, sleep quality, fatigue and daytime sleepiness were studied. Significance was only reached for a smaller subset of the variables, which may be due to lack of power and a type 2 error, but as not only isolated cases but rather groups of variables pointed in the same direction, our data may indicate presence of true differences, which was supported by previous studies also reporting increased daytime sleepiness in craniopharyngioma patients (11, 15) . The patients had significantly higher levels of evening salivary cortisol and plasma free thyroxine suggesting that these findings cannot be ascribed to hypopituitarism per se.
Sleep diary entries and actigraphic recordings were carried out for the assessment of sleep-wake patterns. The sleep diaries provided subjective information on the subjects' sleep habits, while the actigraphs presented an objective view. From the actigraphic data analyses, we included measures of sleep-wake pattern, whereas others also included circadian parameters (31); however, we were not able to draw these measures. When measured from the sleep diaries, patients woke up in the morning about an hour earlier compared with healthy controls, although this finding was only borderline significant when measured from the actigraphy. The discrepancy could be caused by, for example, the actigraphic adjustments and misinterpretation of rest intervals. The actigraphy demonstrated normal rhythmic sleep-wake patterns in alignment with 12 h light:12 h darkness cycle in the whole cohort with no differences comparing patients with healthy controls and with no significant differences within the differentiated subgroups.
Owing to the influence of SCN on sleep and circadian function, the patient's daily melatonin secretion was compared with that of healthy controls. In the total cohort, melatonin concentrations did not differ at any time point, whereas the integrated melatonin concentrations reflected by AUC were lower in the patients compared with controls. In patients, low midnight melatonin concentrations were associated with decreased time of night sleep, decreased total sleep time and impaired sleep efficiency. Furthermore, low midnight melatonin concentrations were borderline associated with increased daytime sleepiness and impaired sleep quality. In healthy controls, similar associations were only observed for time of night sleep. In keeping with our findings, Muller et al. (4) reported in their study of craniopharyngioma patients that decreased night-time melatonin concentration was significantly correlated with increased daytime sleepiness (ESS). In addition, low midnight melatonin was associated with a reduced physical activity assessed by activity counts. It might be speculated that the reduced physical activity could be a reflection of the increased fatigue and sleepiness in patients. Furthermore, as suggested by Harz et al. (32) , reduced physical activity in craniopharyngioma patients might contribute to the development of obesity.
Three different patterns of the individual daily melatonin concentrations of patients were observed, and patients were divided into three subgroups accordingly. Only the six patients with low peak values of melatonin had increased daytime sleepiness, impaired sleep quality and a tendency for increased general and mental fatigue, whereas those with apparently normal secretion did not differ from healthy controls. Lower midnight melatonin concentrations and altered sleep-wake patterns were also described by Lipton et al. (14) . Phase shift in melatonin secretion did not have any obvious influence on sleep characteristics, sleepiness, fatigue, sleep quality or general health by the applied methods. Owing to power limitations, we could not draw conclusions concerning the impact of phase-shifted melatonin secretion on sleep, sleepiness and fatigue. Former studies have reported on a delayed secretory melatonin pattern with peaks in the daytime in patients with delayed sleep-phase syndrome (33) , whereas another study has observed a relatively higher melatonin secretion during the day in narcoleptic patients (34) . Even though secondary narcolepsy is rarely seen, case descriptions of secondary narcolepsy in patients with hypothalamic tumour involvement have been reported (10, 13, 35, 36, 37, 38) . We therefore speculate that the sleep-wake control may be involved, either via involvement of the ventral preoptic nucleus or hypocretinergic neurons located in the hypothalamus or their projections, causing disturbances in sleep regulation or rapid eye movement and non-rapid eye movement transitions.
The daily cortisol profiles from the patients roughly showed the same pattern as healthy controls; however, average patients had higher saliva cortisol concentrations particularly in the evening. Saliva cortisol is generally believed to reflect the free biologically active cortisol concentration, with a tenfold lower concentration compared with serum (39) . It can be speculated that the altered sleep pattern encountered in the patient to some extent could be explained by slight evening/night-time hypercortisolism. In patients, high midnight cortisol had negative effects on sleep with an increased number of awakenings during the night and a tendency towards decreased total sleep time. While midnight melatonin remained independently related to decreased total sleep time after the adjustment for cortisol, high midnight cortisol remained independently related to number of awakenings.
Hypothalamic obesity is a frequent complication of craniopharyngiomas (40) , and previous studies have reported an association between hypothalamic damage on magnetic resonance imaging and postoperative weight gain and obesity (41) . Park et al. (42) observed an increase in BMI Z-scores in the first postoperative year in paediatric craniopharyngioma patients with little or no hypothalamic involvement at the time of diagnosis. Furthermore, they found that none of the patients with no initial hypothalamic involvement were obese, while one-third of the patients with severe hypothalamic involvement were obese. We found that the degree of hypothalamic injury was significantly correlated with a higher BMI, lower self-rated mental health and borderline correlated with lower activity counts. In patients, a higher BMI was associated with increased daytime sleepiness, increased mental fatigue, increased daytime dysfunction and lower self-rated mental health, and it seemed to be associated with impaired sleep efficiency and increased general and physical fatigue. However, these findings were not observed in healthy controls. Obesity is the most common predisposing factor for obstructive sleep apnoea (43) . O'Gorman et al. (44) reported that adolescents with craniopharyngioma-related obesity had more sleepdisordered breathing than BMI-matched healthy controls, and they suggested that the mechanism of obesity, not only the degree of obesity, might influence sleepdisordered breathing. Several factors, and not just the hypothalamic obesity, may thus contribute to the sleep disturbances, fatigue and sleepiness observed in the patients.
Limitations
The majority of the patients included had only mild hypothalamic injury. Exclusion criteria and the extensive protocol might have discouraged patients suffering from severe sequelae, which could result in selective recruitment and reduced the differences observed. The patients and the healthy controls were, however, matched suggesting that differences observed between the groups represented disease-related differences. We were unable to find the relation between melatonin secretion and the degree of hypothalamic injury; the fact whether a more detailed classification as suggested by others (42, 45) would be of any difference remains speculative.
We recognise that several outcome measures were analysed and appreciate the danger of multiple comparisons and the risk of type 1 error. Given the small cohort, differences would have to be far more prominent to present as significant if corrections for multiple comparisons should be applied. The optimal study in such case should include a much larger cohort, which on the other hand is an impossible task given the rarity of the disease. Furthermore, assessment of quality of life may present significant variation due to heterogeneity of the patients.
Melatonin was measured during the night within the actigraphic recording period, thus interrupting natural sleep. As actigraphic recordings were carried out over a 2-week period, the influence of the one interrupted night was minimal. We chose to do saliva sampling parallel to the actigraphic recordings in order to collect all of our data on sleep, sleepiness and fatigue within one occasion to prevent the potential bias of changes over time.
Conclusion
Melatonin rhythms serve as a marker of the circadian function in the SCN. Craniopharyngioma patients presented with significantly decreased AUC melatonin concentrations as compared with healthy controls, and our data indicated a relationship between low midnight melatonin and reduced total sleep time, reduced time of night sleep, impaired sleep efficiency and reduced physical activity. Insight and medical treatment of craniopharyngioma patients is complex, and in order to clarify the altered sleep characteristics, sleepiness and fatigue in craniopharyngioma patients, further research is required.
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